Drugs / ABBV-637
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934889 | Apr 2025 → Apr 2028 expected | gliosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04721015 | Feb 2021 → Feb 2026 overdue | non-small cell lung carcinoma | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-637 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04721015 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT04721015 ↗ |